Dr Reddy's closes Wockhardt branded generics deal on modified terms

Under new terms, DRL to hold back Rs 300 crore and release it if the revenue from sale of the products forming part of the business undertaking during the 12 months post-closing exceeds Rs 480 cr

BS Reporter | Hyderabad
Last Updated at June 10, 2020 17:28 IST

Under the new terms, an amount of Rs 1,483 crore would be paid on the date of closing.

Dr Reddy's Laboratories Limited today announced that it has completed the acquisition of select divisions of Wockhardt Limited's branded generics business in India and a few other international territories of Nepal, Bhutan and Maldives. The deal was completed along with certain changes in the original terms of agreement pertaining to the payment consideration.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

MONTHLY

₹ 249

Select

ANNUAL

₹ 1799

Select

Best Offer

SMART ANNUAL

₹ 1499

₹ 1799

Opt for auto renewal and save Rs 300

Select

What you get on Business Standard Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
Pick your 5 favourite companies, get a daily email with all news updates on them.
26 years of website archives.
Preferential invites to Business Standard events.